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The Power of Collaboration {#sec1.1}
--------------------------

Nevan KroganQuantitative Biosciences Institute (QBI), University of California, San Francisco

While the pandemic has brought immense devastation, I see a silver lining in how it revealed the power of collaboration in science. Watching the outbreak unfold, I told my lab in February to drop everything else and focus our disease-agnostic pipeline on this problem. It was inspiring to see my team rise to the task, dropping individual projects and working together on one shared goal. From the very start, it was obvious that we required help from experts in other areas---for example, there were only very few labs that could do infectious work with the virus at the time. I feel very lucky, but am also a little proud, that the work that we have been doing at UCSF's Quantitative Biosciences Institute is fulfilling the promise that building relationships across disciplines allows scientists across the world to work in a team on larger problems. When results are shared openly, science can progress so much faster. This involves not only academic research, but also the private sector---culminating in drugs that are now being tested in clinical studies months after samples were run on the mass spec. If there is one thing that I hope will stay beyond this challenging time, it is this new way of doing science, which hopefully can combat other diseases in the future.

We Will Weather This Storm {#sec1.2}
--------------------------

Karen VousdenThe Francis Crick Institute

Six months ago, it would have been difficult to contemplate the abrupt changes wrought by the COVID-19 pandemic. Interactions with colleagues have collapsed into hours of virtual meetings---better than nothing, but no substitute for the real thing. While this has been an opportunity to think more deeply about our experiments---and my group are writing thesis introductions, fellowship applications, and reviews with unusual enthusiasm---there is no compensation for the growing anxiety around terminated experiments, paper revisions left hanging, and frustration about when we will be able to implement our finely honed research plans. Layered over this are even deeper concerns about funding cuts and lost opportunities for our next generation of researchers. As Chief Scientist of Cancer Research UK, I am at the coalface here. One of the most difficult and depressing aspects of the crisis is attempting to deal with the swingeing funding cuts that---barring a major injection of donations or government support---will be necessary to accommodate the dramatic drop in our charitable income. My CRUK colleagues and I have spent many hours deliberating how to protect our science, our trainees, and our commitment to cancer patients. This remains an agonizing work in progress; there are no good answers---only hard decisions and a dogged faith that our outstanding research community will weather this storm.

Turning to Testing {#sec1.3}
------------------

Jennifer DoudnaUniversity of California, Berkeley

While I'm not usually involved in conversations about infectious disease and public health, everything changed a few months ago. As the pandemic took hold in the U.S., I knew that the unique research organization that I lead, the Innovative Genomics Institute or IGI, could help. I immediately convened an institute-wide meeting on March 13th to form an action plan.

We quickly identified the dire lack of SARS-CoV-2 testing as an issue we could help solve for our community. Through the extraordinary efforts of a diverse, interdisciplinary team of IGI leaders, scientist volunteers from my lab and others, staff, corporate partners, and philanthropic donors, we set up a clinical COVID-19 diagnostic testing facility in just three weeks. It was one of the most incredible feats of collaboration, planning, and execution that I've witnessed in my entire career.

My major takeaway from this experience is that amazing things can be accomplished when we rally around a shared goal that we feel is deeply important. Since scientists first began to understand the SARS-CoV-2 virus and battle COVID-19, researchers of all kinds have responded by sharing critical innovations, blueprints, and solutions with the world.

Returning to Research {#sec1.4}
---------------------

Brenda A. SchulmanMax Planck Institute of Biochemistry

As research operations partially resume, with numerous measures (including working dispersed, partitioned, and in shifts) to prevent spread of potential infection, we all appreciate precious time in the lab. In the short term, I anticipate renewed productivity bolstered by extreme focus, prioritization, and efficiency. When such practices become engrained, they may even facilitate the balance many students seek. However, looking back at my own time at the bench, what I think will be missed are the spontaneous "what if" experiments, or the rare technical challenges that ultimately lead to unanticipated breakthroughs.

Looking forward, I foresee new stresses on students and postdocs, especially in countries with strict age requirements and time-limits for training periods. The scientific community must adapt from previous bureaucratic strictures and provide guidance and flexibility to the next generation of scientists who are currently anxious about their future prospects. On the positive side, there is growing appreciation for biomedical research across society. Also, new interdisciplinary research streams focusing on pandemic biology will surely blossom.

Finally, while I'm grateful for the interactions made possible by video conferencing, face-to-face meetings build trust, lead to the sharing of secrets, and foster new ideas. There is no substitute for human interactions, especially accidental encounters that can be transformative. I miss my colleagues and will cherish time with them in the future.

A Virtual Laboratory {#sec1.5}
--------------------

Anne-Claude GingrasLunenfeld-Tanenbaum Research Institute

The COVID-19 pandemic has not been "business as usual" for us. We normally develop proteomics approaches to explore cellular organization, focusing on cancer and some rare diseases. We shut down these projects in March and moved to a virtual laboratory (I finally joined Slack...). Supporting students through this transition was only possible because three exceptional postdoctoral fellows (Drs. Youn, Couzens, and Martin) each formed a small focus group to organize our lab around three major themes and led journal clubs and other mentoring activities. This gave me time to support COVID-19 research. Our lab was already in an excellent position to perform proximity interactomes for the viral proteins and their host receptors in basal conditions as well as in infected cells (with Brian Raught and Fritz Roth). However, as our laboratory is located at Mount Sinai Hospital (Toronto)---a center for SARS-CoV-2 testing---we were asked to contribute to COVID-19 testing efforts. In my case, this has been primarily through the implementation of serology assays in our robotics facility that are now used to profile diverse cohorts. This has been a huge learning curve for me that provided me with a new perspective on the healthcare system and immense appreciation for the work of our clinical colleagues.

Forming an Alliance {#sec1.6}
-------------------

Ivan DikicGoethe University

Every era comes with its challenges, but the ongoing COVID-19 pandemic stands out as one of the most urgent and impactful in recent memory. The scientific community has reacted quickly, furthering our understanding of the virus through a culture of collaboration and dedication.

In Frankfurt, we reorganized our institute activities by forming a "CoV-2 team" focused on coronavirus research, while most of the University activities were under lockdown policies. Together with colleagues from the neighboring virology department, we formed a research alliance of biochemists and virologists to tackle our common enemy---SARS-CoV-2. By working together, we have managed to describe proteome changes in human cells upon viral entrance, find drugs and new inhibitors that block viral spread, and determine the role of viral enzymes in regulating virus maturation and anti-viral host immune responses.

Through sharing basic scientific discoveries with our research networks, we were amazed at how colleagues in Munich, Leiden, Freiburg, and Mainz reacted in no time with their contributions relating to this SARS-CoV-2 research. Such cross-border European collaboration and culture of openness has brought some new discoveries, but equally important, it has fostered a sense of purpose, inspiration, and togetherness among our students and postdocs, showing that science is an incredibly rewarding and important profession.
